google-site-verification: googlec7193c3de77668c9.html

EU regulator rejects Alzheimer’s drug lecanemab

Prof Tara Spires-Jones, president of the British Neuroscience Association, said the EMA’s decision will come as “a disappointment to many”.

But she said there were reasons to remain hopeful.

“Lecanemab has shown that it is possible to slow down disease progression, and research does work. Now we need to ramp up our efforts to discover new and safer treatments,” Prof Spires-Jones said.

Prof John Hardy, professor of neuroscience and group leader at the UK Institute for Dementia Research, University College London (UCL), said the decision could have unintended consequences.

“I am sure we will now see rich people with early Alzheimer’s disease flying to the US or other jurisdictions for treatment.”


Source link

Views: 1

See also  How holidays, food and clothes soon cost you more - despite the Iran ceasefire

Check Also

Moscow hit by largest Ukrainian attack since start of Russia's full-scale war

A refinery and a shopping centre were burning after almost 200 Ukrainian drones struck an …

Norway’s crown princess undergoes successful lung transplant, palace says

Høiby, 29, was four when his mother married Crown Prince Haakon and is not himself …

MoD investigating reports Russian warship fired warning shots near yacht in Channel

A UK-registered yacht reported shots were fired by the frigate off the coast of the …

Leave a Reply

Available for Amazon Prime
Hawaii car transport. You have been rate limited for making too many requests in a short time frame. Just a moment....